Suppr超能文献

澳大利亚和英国基于人群的病例携带者的 CDKN2A 突变携带者的黑色素瘤风险。

Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK.

机构信息

Center for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Melbourne, Australia.

出版信息

J Med Genet. 2011 Apr;48(4):266-72. doi: 10.1136/jmg.2010.086538. Epub 2011 Feb 15.

Abstract

BACKGROUND

CDKN2A mutations confer a substantial risk of cutaneous melanoma; however, the magnitude of risk is uncertain.

METHODS

The study estimated the hazard ratio (HR) and the average age specific cumulative risk (ie, penetrance) of reported melanoma for CDKN2A mutation carriers in case families using a modified segregation analysis of the first and higher degree relatives of 35 population-based cases. The study sample included 223 relatives of 13 melanoma cases diagnosed when aged 18-39 years from Melbourne, Sydney and Brisbane, Australia, and 322 relatives of 22 melanoma cases diagnosed at any age from Yorkshire, UK.

RESULTS

The estimated HR for melanoma for mutation carriers relative to the general population decreased with regions of increasing ambient ultraviolet (UV) irradiance, being higher for the UK than Australia (87, 95% CI 50 to 153 vs 31, 95% CI 20 to 50, p=0.008), and across Australia, 49 (95% CI 24 to 98) for Melbourne, 44 (95% CI 22 to 88) for Sydney, and 9 (95% CI 2 to 33) for Brisbane (p=0.02). Penetrance did not differ by geographic region. It is estimated that 16% (95% CI 10% to 27%) of UK and 20% (95% CI 13% to 30%) of Australian CDKN2A mutation carriers would be diagnosed with melanoma by age 50 years, and 45% (95% CI 29% to 65%) and 52% (95% CI 37% to 69%), respectively, by age 80 years.

CONCLUSIONS

Contrary to the strong association between UV radiation exposure and melanoma risk for the general population, CDKN2A mutation carriers appear to have the same cumulative risk of melanoma irrespective of the ambient UV irradiance of the region in which they live.

摘要

背景

CDKN2A 突变赋予了个体罹患皮肤黑色素瘤的高风险;然而,其风险程度尚不确定。

方法

本研究通过对来自澳大利亚墨尔本、悉尼和布里斯班的 35 例发病年龄在 18-39 岁的人群中,以及来自英国约克郡的 22 例任何年龄发病的人群中的病例一级和更高亲属进行改良分离分析,估计了 CDKN2A 突变携带者的病例家族中黑色素瘤的风险比(hazard ratio,HR)和平均年龄特异性累积风险(即外显率)。研究样本包括来自澳大利亚墨尔本、悉尼和布里斯班的 13 例 18-39 岁发病的黑色素瘤病例的 223 名亲属,以及来自英国约克郡的 22 例任何年龄发病的黑色素瘤病例的 322 名亲属。

结果

与普通人群相比,突变携带者罹患黑色素瘤的 HR 随环境紫外线(ultraviolet,UV)辐射区域的增加而降低,英国的 HR 高于澳大利亚(87,95%置信区间为 50 至 153 比 31,95%置信区间为 20 至 50,p=0.008),在澳大利亚,墨尔本为 49(95%置信区间为 24 至 98)、悉尼为 44(95%置信区间为 22 至 88)、布里斯班为 9(95%置信区间为 2 至 33)(p=0.02)。地理区域之间的外显率无差异。预计英国的 16%(95%置信区间为 10%至 27%)和澳大利亚的 20%(95%置信区间为 13%至 30%)CDKN2A 突变携带者将在 50 岁前被诊断为黑色素瘤,分别有 45%(95%置信区间为 29%至 65%)和 52%(95%置信区间为 37%至 69%)将在 80 岁前被诊断为黑色素瘤。

结论

与普通人群中紫外线辐射暴露与黑色素瘤风险之间的强关联相反,CDKN2A 突变携带者似乎具有相同的黑色素瘤累积风险,而与他们居住的地区的环境紫外线辐射无关。

相似文献

6
Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.CDKN2A 种系突变黑色素瘤家系二级亲属的监测。
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1771-7. doi: 10.1158/1055-9965.EPI-13-0130. Epub 2013 Jul 29.

引用本文的文献

7
The Future of Precision Prevention for Advanced Melanoma.晚期黑色素瘤精准预防的未来
Front Med (Lausanne). 2022 Jan 17;8:818096. doi: 10.3389/fmed.2021.818096. eCollection 2021.

本文引用的文献

5
Genetic risk factors for melanoma.黑色素瘤的遗传风险因素。
Hum Genet. 2009 Oct;126(4):499-510. doi: 10.1007/s00439-009-0715-9. Epub 2009 Jul 8.
6
Mutation scanning using high-resolution melting.使用高分辨率熔解曲线分析进行突变扫描
Biochem Soc Trans. 2009 Apr;37(Pt 2):433-7. doi: 10.1042/BST0370433.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验